Investors Buy High Volume of Call Options on uniQure (NASDAQ:QURE)

uniQure (NASDAQ:QURE - Get Free Report) saw some unusual options trading activity on Tuesday. Traders acquired 8,961 call options on the stock. This is an increase of 314% compared to the typical volume of 2,162 call options.

Analysts Set New Price Targets

QURE has been the subject of several research analyst reports. Cantor Fitzgerald raised shares of uniQure to a "strong-buy" rating in a research note on Monday, May 19th. Wells Fargo & Company cut their target price on shares of uniQure from $35.00 to $30.00 and set an "equal weight" rating for the company in a research note on Friday, February 28th. Wall Street Zen raised shares of uniQure from a "sell" rating to a "hold" rating in a research note on Saturday, May 24th. Guggenheim reaffirmed a "buy" rating and set a $28.00 target price on shares of uniQure in a research note on Monday, May 12th. Finally, Chardan Capital reiterated a "buy" rating and set a $38.00 price objective on shares of uniQure in a research report on Friday, May 30th. Four analysts have rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $37.82.

uniQure Price Performance

QURE stock traded up $0.66 during trading on Friday, hitting $17.27. 1,812,893 shares of the company's stock traded hands, compared to its average volume of 1,914,000. uniQure has a 52 week low of $3.73 and a 52 week high of $19.18. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51. The business has a fifty day simple moving average of $12.91 and a 200 day simple moving average of $13.19. The stock has a market capitalization of $945.98 million, a price-to-earnings ratio of -3.48 and a beta of 0.08.

uniQure (NASDAQ:QURE - Get Free Report) last released its quarterly earnings results on Friday, May 9th. The biotechnology company reported ($0.82) EPS for the quarter, topping analysts' consensus estimates of ($1.07) by $0.25. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. The firm had revenue of $1.57 million during the quarter, compared to analysts' expectations of $5.93 million. As a group, research analysts expect that uniQure will post -3.75 EPS for the current fiscal year.

Hedge Funds Weigh In On uniQure

A number of large investors have recently made changes to their positions in QURE. Twin Tree Management LP purchased a new position in shares of uniQure during the 4th quarter worth about $77,000. Mraz Amerine & Associates Inc. purchased a new position in shares of uniQure during the 1st quarter worth about $106,000. OMERS ADMINISTRATION Corp purchased a new position in shares of uniQure during the 1st quarter worth about $152,000. ADAR1 Capital Management LLC purchased a new position in shares of uniQure during the 4th quarter worth about $177,000. Finally, China Universal Asset Management Co. Ltd. boosted its stake in shares of uniQure by 9.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company's stock worth $195,000 after purchasing an additional 969 shares during the period. 78.83% of the stock is owned by hedge funds and other institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.